PT  - JOURNAL ARTICLE
AU  - YAEGASHI, HIROSHI
AU  - IZUMI, KOUJI
AU  - KADOMOTO, SUGURU
AU  - NAITO, RENATO
AU  - MAKINO, TOMOYUKI
AU  - IWAMOTO, HIROAKI
AU  - NOHARA, TAKAHIRO
AU  - SHIGEHARA, KAZUYOSHI
AU  - KADONO, YOSHIFUMI
AU  - MIZOKAMI, ATSUSHI
TI  - High Serum CA19-9 Concentration Indicates High Chemosensitivity and Better Survival in Advanced Urothelial Carcinoma
AID  - 10.21873/anticanres.13122
DP  - 2019 Jan 01
TA  - Anticancer Research
PG  - 375--380
VI  - 39
IP  - 1
4099  - http://ar.iiarjournals.org/content/39/1/375.short
4100  - http://ar.iiarjournals.org/content/39/1/375.full
SO  - Anticancer Res2019 Jan 01; 39
AB  - Background: The present study was conducted to investigate whether baseline serum carbohydrate antigen (CA) 19-9 predicts prognosis or treatment effect in patients with advanced urothelial carcinoma (UC). Materials and Methods: We retrospectively analyzed data of patients diagnosed with locally advanced or metastatic or recurrent UC between April 2008 and November 2014. CA19-9 was determined using enzyme-linked immunosorbent assay (ELISA) and the relationship between CA19-9 and prognosis were analyzed. Results: Of 40 patients, seven with CA19-9 ≤2 U/ml who were suspected of having Lewis A-negative blood type and two patients with advanced metastatic liver disease were excluded. UC-specific survival in metastatic disease significantly correlated with prognosis (p=0.018). Overall survival in patients with high serum CA19-9 demonstrated a significantly better prognosis than in those with low concentrations (log-rank test, p=0.032). Conclusion: High baseline serum CA19-9 may predict a good prognosis in patients with advanced UC.